Chapter 5: Biotechnological Applications in Medicine
Recombinant DNA technology lets us mass-produce safe, effective medicines, diagnose disease early and even correct a faulty gene. Human-like products made this way avoid the unwanted immune reactions that animal-derived products can cause.
What you will learn
Why animal insulin caused problems and how human insulin is made in E. coli.
The structure of insulin: A and B chains, disulphide bridges, proinsulin and C-peptide.
Gene therapy, using ADA deficiency as the example.
Molecular diagnosis with PCR, ELISA and DNA probes.
How recombinant vaccines are made.
5.1 Recombinant therapeutics
Recombinant DNA technology allows mass production of safe and more effective therapeutic drugs. Because the protein is the human version, it does not set off unwanted immune responses, as products from non-human sources sometimes do.
About 30 recombinant therapeutics have been approved for human use worldwide, and 12 of these are marketed in India (as given in NCERT; the number keeps growing). Examples include human insulin, human growth hormone, interferons and the hepatitis B vaccine.
5.2 Genetically engineered insulin
Many people with diabetes manage it by regular doses of insulin. Earlier, insulin was extracted from the pancreas of slaughtered cattle and pigs. Two problems arose:
Some patients developed allergy or other reactions to the foreign protein.
Supply depended on the meat industry and could not keep pace with demand.
Structure of insulin
Insulin is made of two short polypeptide chains, chain A and chain B. They are linked together by disulphide bridges. Chain A has 21 amino acids and chain B has 30, so mature insulin has 51 amino acids in all.
In mammals, including humans, insulin is not made in its final form. It is first synthesised as a pro-hormone, proinsulin. Proinsulin has an extra stretch called the C-peptide, which joins the A and B chains. During maturation the C-peptide is cut out. Mature insulin does not contain the C-peptide.

In proinsulin the C-peptide links the end of chain B to the start of chain A; once it is cut out, only the two chains held by disulphide bridges remain.
How Eli Lilly made human insulin
The main challenge was getting insulin assembled into its mature form. A bacterium cannot process proinsulin the way a human pancreas does. The solution side-stepped this problem.
In 1983, the American company Eli Lilly prepared two DNA sequences, one for chain A and one for chain B of human insulin.
Each sequence was introduced into plasmids of E. coli.
The bacteria produced the A and B chains separately.
The chains were extracted and combined by creating disulphide bonds.
The result was human insulin, sold as Humulin.
| Feature | Animal insulin | Recombinant human insulin |
|---|---|---|
| Source | Pancreas of cattle and pigs | E. coli carrying A- and B-chain genes |
| Protein | Slightly different from human | Identical to human |
| Immune reaction | Allergy in some patients | Not expected |
| Supply | Limited by slaughter | Can be scaled in bioreactors |
5.3 Gene therapy
If a child is born with a hereditary disease, can we correct it? Gene therapy is a collection of methods that allows correction of a gene defect diagnosed in a child or an embryo. Genes are inserted into a person's cells and tissues to treat the disease. A normal gene is delivered to take over the function of, and compensate for, the non-functional gene.
The first case: ADA deficiency (1990)
The first clinical gene therapy was given in 1990 to a 4-year-old girl with adenosine deaminase (ADA) deficiency.
ADA is an enzyme needed for the immune system to work.
The disorder is caused by deletion of the gene for ADA.
Without ADA, the child's immune system fails, and ordinary infections become dangerous.
| Treatment | How it works | Limitation |
|---|---|---|
| Bone marrow transplantation | Healthy donor marrow supplies ADA-producing cells | Needs a matching donor |
| Enzyme replacement therapy | Functional ADA is given by injection | Not completely curative; repeated doses |
| Gene therapy (1990) | Patient's own lymphocytes are given a working ADA gene | Periodic infusions needed |
Steps of ADA gene therapy
Lymphocytes are taken from the patient's blood and grown in culture outside the body.
A functional ADA cDNA is introduced into these lymphocytes using a retroviral vector.
The engineered lymphocytes are returned to the patient.
These cells are not immortal. So the patient needs periodic infusions of such engineered lymphocytes.
A permanent cure is possible if the gene isolated from marrow cells producing ADA is introduced into cells at early embryonic stages.
5.4 Molecular diagnosis
Early diagnosis means early and effective treatment. Conventional methods, such as serum and urine analysis, cannot detect a disease early. Recombinant DNA technology, PCR and ELISA can.
PCR
A pathogen is usually suspected only after symptoms appear. By then, its concentration in the body is already very high. PCR can amplify the nucleic acid of a pathogen present in very low amounts, before symptoms show.
PCR is now routinely used to:
detect HIV in suspected AIDS patients,
detect mutations in genes of suspected cancer patients,
identify many other genetic disorders.
DNA or RNA probes
A probe is a single-stranded DNA or RNA tagged with a radioactive molecule.
The probe is allowed to hybridise to its complementary DNA in a clone of cells.
The clones are then detected by autoradiography (exposure to photographic film).
A clone with a mutated gene will not appear on the film, because the probe is not complementary to the mutated gene.
ELISA
ELISA (enzyme-linked immunosorbent assay) is based on the principle of antigen–antibody interaction. An infection can be detected in two ways:
by the presence of antigens of the pathogen (proteins, glycoproteins), or
by the presence of antibodies the body has made against the pathogen.
| Method | Detects | Principle |
|---|---|---|
| PCR | Pathogen nucleic acid, mutations | Amplification of DNA |
| Probe | A specific normal or mutated gene | Hybridisation + autoradiography |
| ELISA | Antigens or antibodies | Antigen–antibody interaction |
5.5 Vaccine production
A vaccine trains the immune system using an antigen. Older vaccines used killed or weakened pathogens. Recombinant DNA technology offers a safer route.
The gene for an antigenic protein of the pathogen is identified.
It is inserted into a suitable host, such as yeast or a bacterium.
The host produces the antigenic polypeptide in large amounts in a bioreactor.
The protein is purified (downstream processing) and formulated as a vaccine.
The classic example is the hepatitis B vaccine, produced from recombinant yeast that makes the surface antigen of the virus.
Why this is better:
The vaccine has only one protein, not the whole live pathogen, so it cannot cause the disease.
It can be made in large amounts with uniform quality.
Worked examples: Chapter 5
Worked example 5.1: A patient has used pig insulin for years and develops rashes after each dose. What changes when he switches to Humulin?
Solution: Pig insulin is a foreign protein, so his immune system reacts to it. Humulin is identical to human insulin, so such reactions are not expected.
Worked example 5.2: Why did Eli Lilly make the A and B chains separately instead of making proinsulin in E. coli?
Solution: E. coli cannot process proinsulin by cutting out the C-peptide. Making each chain separately and then joining them by disulphide bonds avoids the need for that maturation step.
Worked example 5.3: How many amino acids are there in mature human insulin? Which part of proinsulin is missing from it?
Solution: Chain A (21) + chain B (30) = 51 amino acids. The C-peptide is removed during maturation.
Worked example 5.4: List the steps of gene therapy for ADA deficiency in order.
Solution: Collect lymphocytes from blood → grow them in culture → introduce functional ADA cDNA using a retroviral vector → return the cells to the patient → repeat periodically.
Worked example 5.5: Why is the 1990 gene therapy not a permanent cure, and how could it be made permanent?
Solution: Lymphocytes are not immortal; they die and the corrected cells are lost. Introducing the ADA gene from marrow cells into cells at early embryonic stages could give a permanent cure.
Worked example 5.6: A radioactive probe for the normal form of a gene is used on four clones, P, Q, R and S. On the film, P, R and S show dark spots; Q shows nothing. What does this mean?
Solution: The probe hybridised to P, R and S, so they carry the normal sequence. Q shows no signal because its gene is mutated and does not pair with the probe.
Worked example 5.7: A blood sample is tested for HIV by ELISA. What two kinds of molecules could the test look for?
Solution: Viral antigens (such as viral proteins) or antibodies made by the patient against HIV. Both rely on antigen–antibody interaction.
Worked example 5.8: Why is a recombinant hepatitis B vaccine safer than a vaccine made from live virus?
Solution: It contains only the purified surface protein made by yeast. With no viral genome present, it cannot cause infection, yet it still triggers antibodies.
Quick revision
Earlier insulin came from cattle and pig pancreas; caused allergy in some patients.
Insulin = chain A + chain B, joined by disulphide bridges; made as proinsulin with a C-peptide that is removed.
Eli Lilly, 1983: A and B chains made separately in E. coli, then joined → Humulin.
Gene therapy: first in 1990, 4-year-old girl, ADA deficiency (gene deleted).
ADA therapy: lymphocytes + ADA cDNA via retroviral vector; periodic, since cells are not immortal.
PCR detects tiny amounts of pathogen DNA (HIV, cancer mutations).
Probe + autoradiography: mutated clone gives no signal. ELISA: antigen–antibody.
Recombinant vaccines, e.g. hepatitis B from yeast, contain only an antigen.
NEET traps
Mature insulin has no C-peptide. Proinsulin has it.
Eli Lilly made the two chains separately, not proinsulin.
ADA deficiency is caused by gene deletion; gene therapy used lymphocytes, not RBCs or liver cells.
Enzyme replacement therapy is not curative; gene therapy (as done in 1990) is not permanent either.
In probe tests, the mutated clone is the one that does NOT show up.
ELISA can detect antigens or antibodies; it is not a DNA amplification method.
Practice MCQs: Chapter 5
Level 1: Concept check
1. Human insulin made by recombinant DNA technology was first prepared by (a) Monsanto (b) Eli Lilly (c) Bayer (d) Biocon
2. Eli Lilly prepared human insulin using recombinant DNA in (a) 1972 (b) 1990 (c) 1963 (d) 1983
3. Mature human insulin consists of (a) a single polypeptide chain (b) three chains, A, B and C (c) two chains, A and B, linked by disulphide bridges (d) two chains joined only by hydrogen bonds
4. The extra stretch present in proinsulin but removed during maturation is the (a) A-peptide (b) B-peptide (c) signal sequence of chain A (d) C-peptide
5. The first clinical gene therapy was given in (a) 1990 (b) 1983 (c) 1972 (d) 2002
6. ADA stands for (a) adenine deoxyribose amidase (b) adenylate dehydrogenase (c) adenosine diphosphatase (d) adenosine deaminase
7. ELISA works on the principle of (a) DNA hybridisation (b) antigen–antibody interaction (c) DNA amplification (d) separation by charge
8. The recombinant hepatitis B vaccine is produced using (a) Bacillus thuringiensis (b) yeast (c) Agrobacterium tumefaciens (d) Thermus aquaticus
9. Clones that bind a radioactive probe are detected by (a) gel electrophoresis (b) ELISA (c) PCR (d) autoradiography
10. Before recombinant insulin, insulin for patients came from (a) human placenta (b) the pancreas of slaughtered cattle and pigs (c) E. coli (d) yeast
Level 2: NEET standard
11. The main problem with insulin from animals was that (a) it was too cheap to make (b) it had no B chain (c) it could not lower blood sugar at all (d) some patients developed allergy or other reactions to the foreign protein
12. The main challenge in making insulin by recombinant DNA technology was (a) getting insulin assembled into its mature form (b) finding a bacterial host (c) cutting the DNA (d) the lack of DNA ligase
13. In the method used by Eli Lilly, (a) proinsulin was made and the C-peptide removed inside E. coli (b) one gene for the whole insulin molecule was used (c) the chains were made in yeast (d) chains A and B were made separately in E. coli, extracted and joined by disulphide bonds
14. In gene therapy for ADA deficiency, the cells that receive the functional gene are (a) liver cells (b) red blood cells (c) lymphocytes (d) neurons
15. The functional ADA cDNA is introduced into the patient's cells using a (a) Ti plasmid (b) retroviral vector (c) pBR322 plasmid (d) gene gun
16. Patients given ADA gene therapy need periodic infusions because (a) the gene is cut out of the DNA at once (b) the ADA enzyme is destroyed by antibodies (c) the engineered lymphocytes are not immortal (d) the retrovirus kills the lymphocytes
17. In molecular diagnosis, PCR is useful because it can (a) detect bacteria only at high concentration (b) measure blood glucose (c) completely replace antibody tests (d) detect very small amounts of a pathogen's nucleic acid, such as HIV
18. A probe used in molecular diagnosis is (a) a single-stranded DNA or RNA tagged with a radioactive molecule (b) a double-stranded protein (c) a restriction enzyme (d) a bacterial plasmid
19. Match Column I with Column II. Column I: A. ELISA B. PCR C. Probe D. Gene therapy Column II: i. Antigen–antibody interaction ii. Amplification of nucleic acid iii. Autoradiography iv. ADA deficiency (a) A-i, B-ii, C-iii, D-iv (b) A-ii, B-i, C-iii, D-iv (c) A-i, B-iii, C-ii, D-iv (d) A-iv, B-ii, C-iii, D-i
20. The main limitation of conventional serum and urine tests is that they (a) are too costly (b) cannot detect disease early (c) need PCR to run (d) harm the patient
21. ADA deficiency is caused by (a) deletion of the gene for ADA (b) excess ADA in blood (c) a viral infection (d) non-disjunction of chromosome 21
22. Which of these is NOT a treatment for ADA deficiency? (a) Bone marrow transplantation (b) Enzyme replacement therapy (c) Injection of Bt toxin (d) Gene therapy
Level 3: Challenge
23. A radioactive probe for the normal form of a gene is used on a set of clones. A clone carrying the mutated gene will (a) give no signal on the film, as the probe does not hybridise with it (b) give the strongest signal (c) give two signals (d) be cut by the probe
24. How many amino acids are there in mature human insulin? (a) 21 (b) 30 (c) 51 (d) 86
25. A permanent cure for ADA deficiency could come from (a) weekly injections of ADA enzyme (b) a single transfusion of normal lymphocytes (c) introducing the ADA gene from marrow cells into cells at early embryonic stages (d) destroying the patient's bone marrow
26. A recombinant hepatitis B vaccine is considered safe mainly because (a) it has only an antigenic protein, not the whole live virus (b) it contains live, weakened virus (c) it contains ready-made antibodies (d) it contains viral DNA that multiplies slowly
27. Which statements are correct? I. Mature insulin contains the C-peptide. II. Recombinant human insulin avoids the allergic reactions seen with animal insulin. III. ELISA can detect infection through antigens or through antibodies against the pathogen. IV. The first gene therapy was for cystic fibrosis. (a) I and II (b) II and IV (c) II and III (d) I, III and IV
28. To detect HIV in a suspected patient when the virus is still present in very low amounts, the best method is (a) urine analysis (b) blood glucose test (c) chest X-ray (d) PCR
29. Assertion (A): Mature insulin contains the C-peptide. Reason (R): In mammals, insulin is synthesised as proinsulin, which has an extra stretch called the C-peptide. (a) Both true, R explains A (b) Both true, R does not explain A (c) A true, R false (d) A false, R true
30. Statement I: The first clinical gene therapy was given in 1983 to a child with diabetes. Statement II: In ADA gene therapy, engineered lymphocytes are returned to the patient once and are never needed again. (a) Both true (b) Both false (c) I true, II false (d) I false, II true
Answer key with reasons
| Q | Ans | Reason |
|---|---|---|
| 1 | b | Eli Lilly made Humulin. |
| 2 | d | It was done in 1983. |
| 3 | c | A and B chains, disulphide bridges. |
| 4 | d | C-peptide is removed. |
| 5 | a | 1990, for ADA deficiency. |
| 6 | d | Adenosine deaminase. |
| 7 | b | ELISA uses antigen–antibody binding. |
| 8 | b | Recombinant yeast makes the antigen. |
| 9 | d | Radioactive probes are seen by autoradiography. |
| 10 | b | Cattle and pig pancreas. |
| 11 | d | Foreign protein caused reactions. |
| 12 | a | Assembly into mature form was the hurdle. |
| 13 | d | Separate chains, then disulphide bonds. |
| 14 | c | Lymphocytes were engineered. |
| 15 | b | A retroviral vector carried the cDNA. |
| 16 | c | Lymphocytes have a limited life. |
| 17 | d | PCR amplifies tiny amounts of nucleic acid. |
| 18 | a | Definition of a probe. |
| 19 | a | Each method matched to its principle or use. |
| 20 | b | They miss early disease. |
| 21 | a | ADA gene deletion. |
| 22 | c | Bt toxin is an insecticide. |
| 23 | a | No complementarity, no signal. |
| 24 | c | 21 + 30 = 51. |
| 25 | c | Early embryonic correction is permanent. |
| 26 | a | Only one protein, no live virus. |
| 27 | c | I and IV are false. |
| 28 | d | PCR detects low pathogen levels. |
| 29 | d | C-peptide is removed, so A is false; R is true. |
| 30 | b | 1990, ADA; infusions are periodic. |
Chapter 5 revision sheet
One-page summary
Recombinant therapeutics are safe and effective and avoid unwanted immune reactions seen with animal products; about 30 are approved worldwide.
Older insulin came from cattle and pig pancreas; some patients developed allergy to it.
Insulin has two short chains, A and B, linked by disulphide bridges.
It is made as proinsulin, which has an extra stretch, the C-peptide; the C-peptide is removed in mature insulin.
Eli Lilly (1983) made DNA for chains A and B, put them into plasmids of E. coli, made the chains separately, then joined them by disulphide bonds (human insulin).
Gene therapy corrects a gene defect by putting a normal gene into a person's cells or tissues.
First clinical gene therapy: 1990, a 4-year-old girl with adenosine deaminase (ADA) deficiency.
ADA deficiency comes from deletion of the ADA gene; ADA is needed for the immune system.
Other treatments: bone marrow transplant and enzyme replacement therapy (injected ADA); neither is a complete cure.
Method: patient's lymphocytes grown in culture → functional ADA cDNA added with a retroviral vector → cells returned to the patient.
Lymphocytes are not immortal, so infusions must be repeated; putting the gene into early embryonic cells could give a permanent cure.
Early diagnosis needs methods that work before symptoms: PCR, probes with autoradiography, and ELISA.
PCR amplifies tiny amounts of pathogen nucleic acid (HIV in suspected AIDS; mutations in suspected cancer).
A radioactive single-stranded probe binds its complementary DNA; a clone with a mutated gene gives no spot on the film.
ELISA uses antigen–antibody binding to detect antigens or antibodies; recombinant vaccines (e.g. hepatitis B from yeast) carry only an antigen.
Must-remember table
| Item | Key fact | Linked term |
|---|---|---|
| Chain A / chain B | 21 / 30 amino acids | Joined by disulphide bridges |
| C-peptide | Removed from proinsulin | Absent in mature insulin |
| Eli Lilly, 1983 | Chains made separately in E. coli | Human insulin |
| ADA deficiency | ADA gene deleted | Immune failure |
| First gene therapy | 1990, 4-year-old girl | Retroviral vector, lymphocytes |
| PCR diagnosis | Amplifies pathogen DNA/RNA | HIV, cancer mutations |
| Probe + autoradiography | Labelled single-stranded DNA/RNA | Mutated clone shows no spot |
| ELISA | Antigen–antibody binding | Detects antigen or antibody |
| Recombinant vaccine | Antigen only, made in a host | Hepatitis B vaccine from yeast |
Memory aids
"21 + 30 = 51": chain A has 21 amino acids, chain B has 30; mature insulin has 51.
"C is Cut": the C-peptide is cut out of proinsulin.
"A-D-A in 1-9-9-0, age 4": ADA gene therapy, 1990, a 4-year-old girl.
"Lymphocytes Leave": engineered lymphocytes are mortal, so they leave and the treatment is repeated.
"PEP" diagnosis: PCR, ELISA, Probe.
Concept connections
Insulin and blood glucose control come from NEET Biology Book 5: Human Physiology (endocrine system).
Antigens, antibodies, vaccines, AIDS and cancer link to NEET Biology Book 8: Biology and Human Welfare.
cDNA, reverse transcription and gene mutation come from NEET Biology Book 7: Genetics and Evolution.
Practice MCQs: Chapter 5, Level 4 (new NEET pattern)
31. Match List I with List II. List I: A. Chains A and B B. C-peptide C. Disulphide bridges D. Proinsulin List II: i. Extra stretch removed during maturation ii. Bonds that link the two chains iii. Two short polypeptide chains of mature insulin iv. Pro-hormone form of insulin (a) A-iv, B-i, C-ii, D-iii (b) A-iii, B-ii, C-i, D-iv (c) A-iii, B-i, C-ii, D-iv (d) A-i, B-iii, C-ii, D-iv
32. Match List I with List II. List I: A. PCR B. ELISA C. Radioactive probe D. Autoradiography List II: i. Based on antigen–antibody binding ii. Amplifies very small amounts of pathogen nucleic acid iii. Shows on photographic film where the probe bound iv. Labelled single-stranded nucleic acid that pairs with its complement (a) A-ii, B-i, C-iv, D-iii (b) A-i, B-ii, C-iv, D-iii (c) A-ii, B-i, C-iii, D-iv (d) A-ii, B-iv, C-i, D-iii
33. Match List I with List II. List I: A. 1983 B. 1990 C. Hepatitis B vaccine D. Retroviral vector List II: i. Eli Lilly's human insulin ii. First clinical gene therapy iii. Carries ADA cDNA into lymphocytes iv. Recombinant antigen made in yeast (a) A-ii, B-i, C-iv, D-iii (b) A-i, B-ii, C-iv, D-iii (c) A-i, B-ii, C-iii, D-iv (d) A-i, B-iv, C-ii, D-iii
34. Match the ADA treatments in List I with List II. List I: A. Bone marrow transplant B. Enzyme replacement therapy C. Gene therapy with lymphocytes D. Gene put into early embryonic cells List II: i. Could give a permanent cure ii. Functional ADA given by injection iii. Healthy marrow cells given to the patient iv. Needs repeated infusion of engineered cells (a) A-ii, B-iii, C-iv, D-i (b) A-iii, B-ii, C-i, D-iv (c) A-iii, B-iv, C-ii, D-i (d) A-iii, B-ii, C-iv, D-i
35. Choose the correct set of statements. A. Insulin from cattle and pigs caused allergy in some patients. B. Mature insulin still contains the C-peptide. C. Eli Lilly made chains A and B separately in E. coli. D. The two chains were joined by disulphide bonds. (a) A, C and D only (b) A and B only (c) B, C and D only (d) A, B, C and D
36. How many of the following statements about ADA gene therapy are correct? A. ADA deficiency is caused by deletion of the gene for adenosine deaminase. B. ADA is needed for the immune system to work. C. The patient's lymphocytes are grown in culture outside the body. D. A functional ADA cDNA is introduced using a retroviral vector. E. One infusion cures the patient for life. (a) Five (b) Three (c) Two (d) Four
37. Choose the correct set of statements about molecular diagnosis. A. Serum and urine tests cannot pick up an infection at a very early stage. B. PCR can detect HIV in suspected AIDS patients. C. ELISA can detect either the antigen or the antibodies made against a pathogen. D. A clone with a mutated gene gives a strong spot on the photographic film. (a) A and D only (b) A, B and C only (c) B, C and D only (d) C and D only
38. How many of the following statements are correct? A. Recombinant therapeutics avoid unwanted immune reactions seen with products from non-human sources. B. About 30 recombinant therapeutics are approved for human use worldwide. C. The recombinant hepatitis B vaccine contains the whole live virus. D. A recombinant vaccine carries only an antigen protein, so it cannot cause the disease. (a) One (b) Two (c) Three (d) Four
39. Four bacterial clones (1–4) are tested with a radioactive probe for the normal form of a gene. After autoradiography, the film shows dark spots at clones 1, 2 and 4, and no spot at clone 3. Which clone carries the mutated gene? (a) 1 (b) 2 (c) 4 (d) 3
40. An ELISA test for a viral antigen gives these results.
| Well | Sample | Colour |
|---|---|---|
| 1 | Patient P | Strong |
| 2 | Patient Q | None |
| 3 | Patient R | Strong |
| 4 | Negative control | None |
Which patients carry the viral antigen? (a) P and R (b) Q only (c) P, Q and R (d) None
41. A table lists the chains of mature human insulin: chain A has 21 amino acids and chain B has 30 amino acids. How many amino acids does mature insulin have in all? (a) 81 (b) 30 (c) 51 (d) 21
Case for Q42–43: A 3-year-old girl keeps falling ill with infections. Tests show she makes no adenosine deaminase. Doctors take her lymphocytes, grow them in culture, add a normal ADA cDNA with a retroviral vector, and infuse the cells back. She improves, but she needs the treatment again after some months.
42. Why must the treatment be repeated? (a) The retroviral vector kills the lymphocytes (b) The ADA cDNA is lost within hours (c) Lymphocytes are not immortal, so the engineered cells die over time (d) Her immune system rejects her own cells
43. What could give her a permanent cure? (a) A larger dose of engineered lymphocytes (b) Introducing the ADA gene from marrow cells into cells at an early embryonic stage (c) Regular injections of ADA enzyme (d) A PCR test every month
44. Why was making human insulin by rDNA technology difficult at first? (a) Humans have no insulin gene (b) Insulin is a lipid (c) E. coli cannot take up plasmids (d) Insulin is made as proinsulin that must be processed, so Eli Lilly made chains A and B separately
45. Which pair is mismatched? (a) ELISA – amplifies nucleic acid (b) PCR – detects HIV in suspected AIDS patients (c) Radioactive probe – autoradiography (d) Eli Lilly – human insulin
Level 4 answer key
| Q | Ans | Reason |
|---|---|---|
| 31 | c | A and B are the chains; C-peptide removed; disulphide links; proinsulin is the pro-hormone |
| 32 | a | PCR amplifies; ELISA = antigen–antibody; probe pairs; autoradiography shows spots |
| 33 | b | 1983 insulin; 1990 gene therapy; hepatitis B antigen in yeast; retrovirus carries ADA cDNA |
| 34 | d | Marrow transplant; enzyme injection; lymphocyte therapy repeated; embryonic route permanent |
| 35 | a | B is false: the C-peptide is removed |
| 36 | d | A–D true; lymphocytes are mortal, so it is repeated |
| 37 | b | A mutated clone does not bind the probe, so it shows no spot |
| 38 | c | C is false: it contains only an antigen protein |
| 39 | d | No spot = probe did not bind = mutated gene |
| 40 | a | Colour appears only where antigen is present: P and R; Q matches the negative control |
| 41 | c | 21 + 30 = 51 |
| 42 | c | Engineered lymphocytes have a limited life |
| 43 | b | Gene in early embryonic cells could cure permanently |
| 44 | d | Proinsulin processing was the hurdle |
| 45 | a | ELISA uses antigen–antibody binding, not amplification |